PARSITAN 50 TABLET

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

ETHOPROPAZINE (ETHOPROPAZINE HYDROCHLORIDE)

Available from:

SEARCHLIGHT PHARMA INC

ATC code:

N04AA05

INN (International Name):

PROFENAMINE

Dosage:

50MG

Pharmaceutical form:

TABLET

Composition:

ETHOPROPAZINE (ETHOPROPAZINE HYDROCHLORIDE) 50MG

Administration route:

ORAL

Units in package:

100

Prescription type:

Prescription

Therapeutic area:

ANTIPARKINSONIAN AGENTS

Product summary:

Active ingredient group (AIG) number: 0106207001; AHFS:

Authorization status:

APPROVED

Authorization date:

2000-11-09

Summary of Product characteristics

PRODUCT MONOGRAPH
Pr
PARSITAN 50
Ethopropazine Hydrochloride Tablets
Tablet, 50 mg ethopropazine (as ethopropazine hydrochloride), Oral
Manufacturer’s Standard
Antiparkinsonian Agent
Searchlight Pharma Inc.
1600 Notre-Dame West, Suite 312
Montreal, Quebec
H3J 1M1
Date of Preparation:
OCT 06, 2022
Submission Control No: 267409
STRUCTURAL FORMULA AND CHEMISTRY
Parsitan 50 is 10-2(2-diethylaminopropyl)phenothiazine. Its structural
formula may be represented as follows:
Molecular formula:
C
19
H
24
N
2
S HCl
Molecular weight:
348.92
Melting point:
233 - 225°C
It is a fine, white, odorless and non-hygroscopic crystalline powder.
It is soluble in absolute alcohol and
chloroform, slightly soluble in water at 20°C, very slightly soluble
in acetone and insoluble in ether and
benzene.
ACTION
Parsitan 50 is an antiparkinsonian agent with potent anticholinergic,
para-sympatholytic and antispasmodic
activities but with weak adrenolytic and antihistaminic effects. It
exerts a strong antagonist action against
nicotine-induced convulsions.
INDICATIONS
In the symptomatic treatment of drug-induced extrapyramidal reactions
and of the manifestations (rigidity,
akinesia, sialorrhea, oculogyric crisis, tremor, etc.) of Parkinson's
disease of encephalitic, arteriosclerotic or
idiopathic origin.
CONTRAINDICATIONS
Glaucoma and hypersensitivity to phenothiazine drugs are the usual
contraindications to the use of Parsitan
50.
WARNING
Because of its anticholinergic effects, administer Parsitan 50 with
great caution in patients with prostatic
hypertrophy, pyloric stenosis of cardiovascular diseases.
PRECAUTIONS
Parsitan 50 treatment should be instituted in low doses which should
be increased progressively until a
satisfactory maintenance dosage is obtained. When substituting
Parsitan 50 for another antiparkinsonian reduce
the dosage of the former drug slowly, while progressively increasing
the Parsitan 50 dosage: its dosage should
be reduced gradually.
Phenothiazines may in rare instances cause blood dyscrasias. Even if
no such case has